ESLA on Nasdaq
Estrella Immunopharma, Inc.
Biological products company, listed on Nasdaq (ESLA). Summary from the record
Price unavailable
Last updated Oct 19, 2026.
Overview
- TickerESLA on Nasdaq1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersEmeryville, California1
- Business address5858 Horton Street, Suite 370, Emeryville, Ca 946082
- Filer category, Emerging growth company2
See how the biggest companies compare on our leaderboards
Effectively progress EB103, our lead product candidate, through clinical development. We believe our autologous T-cell therapies have the potential to overcome major limitations of currently approved CAR-T cells with superior safety and efficacy, allowing access to significantly more patients. As of December 2025, we have completed the dosing of nine patients in the Phase I dose escalation phase of STARLIGHT-1 and have initiated Phase II dose expansion phase at the RP2D. We anticipate completing the Phase II portion of the STARLIGHT-1 clinical trial in 1H2027.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 1 fiscal year, latest first.6
| Period ending | 2025-12-31 |
|---|---|
| Research and development (including $10,125,000 for the year ended December 31, 2025 and $2,801,435 for the six months ended December 31, 2024, from a related party) | $10.2M |
| General and administrative | $2.8M |
| Total operating expenses | $13.1M |
| Loss from Operations | -$13.1M |
| Loss before income taxes | -$13.1M |
| Income tax provision | -$838 |
| Net loss | -$13.1M |
| Net loss applicable to common stock per share, basic (in Dollars per share) | -$0.35 |
| Net loss applicable to common stock per share, diluted (in Dollars per share) | -$0.35 |
| Weighted average common stock outstanding, basic (in Shares) | 36.8M shares |
| Weighted average common stock outstanding, diluted (in Shares) | 36.8M shares |
| Research and development - related party | $10.1M |
| General and administrative - related party | $265.4K |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $1.4M | $916.9K | |
| Prepaid expenses and other receivable | $292.7K | $723.9K | |
| Total current assets | $1.7M | $1.6M | |
| Prepaid expenses, related party , non-current | $1.5M | $1.5M | |
| Total Assets | $3.2M | $3.1M | |
| Other payables and accrued liabilities | $238.4K | $201.8K | |
| Derivative liabilities | $356.5K | ||
| Franchise tax payable | $4.1K | ||
| Income tax payable | $50 | ||
| Total current liabilities | $13.5M | $3.0M | |
| Total Liabilities | $13.5M | $3.0M | |
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 38,486,219 and 36,680,870 shares issued as of December 31, 2025 and 2024, respectively | $3.8K | $3.7K | |
| Additional paid-in capital | $27.2M | $24.6M | |
| Accumulated deficit | -$37.0M | -$23.9M | |
| Treasury stock, at cost 515,281 and 486,979 shares as of December 31, 2025 and 2024, respectively | -$598.4K | -$568.9K | |
| Total Stockholders (Deficit) Equity | -$10.4M | $143.7K | $4.3M |
| Total Liabilities and Stockholders (Deficit) Equity | $3.2M | $3.1M | |
| Preferred Stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred Stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Preferred Stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Preferred Stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 250.0M shares | 250.0M shares | |
| Common stock, shares issued (in Shares) | 38.5M shares | 36.7M shares | |
| Treasury stock, cost (in Shares) | 515.3K shares | 487.0K shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2024-06-30 |
|---|---|---|---|
| Cash and cash equivalents | $1.4M | $916.9K | |
| Prepaid expenses and other receivable | $292.7K | $723.9K | |
| Total current assets | $1.7M | $1.6M | |
| Prepaid expenses, related party , non-current | $1.5M | $1.5M | |
| Total Assets | $3.2M | $3.1M | |
| Other payables and accrued liabilities | $238.4K | $201.8K | |
| Derivative liabilities | $356.5K | ||
| Franchise tax payable | $4.1K | ||
| Income tax payable | $50 | ||
| Total current liabilities | $13.5M | $3.0M | |
| Total Liabilities | $13.5M | $3.0M | |
| Common stock, $0.0001 par value; 250,000,000 shares authorized; 38,486,219 and 36,680,870 shares issued as of December 31, 2025 and 2024, respectively | $3.8K | $3.7K | |
| Additional paid-in capital | $27.2M | $24.6M | |
| Accumulated deficit | -$37.0M | -$23.9M | |
| Treasury stock, at cost 515,281 and 486,979 shares as of December 31, 2025 and 2024, respectively | -$598.4K | -$568.9K | |
| Total Stockholders (Deficit) Equity | -$10.4M | $143.7K | $4.3M |
| Total Liabilities and Stockholders (Deficit) Equity | $3.2M | $3.1M | |
| Preferred Stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Preferred Stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares | |
| Preferred Stock, shares issued (in Shares) | 0 shares | 0 shares | |
| Preferred Stock, shares outstanding (in Shares) | 0 shares | 0 shares | |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in Shares) | 250.0M shares | 250.0M shares | |
| Common stock, shares issued (in Shares) | 38.5M shares | 36.7M shares | |
| Treasury stock, cost (in Shares) | 515.3K shares | 487.0K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 1 fiscal year, latest first.6
| Period ending | 2025-12-31 |
|---|---|
| Net loss | -$13.1M |
| Stock-based compensation | $619.0K |
| Change in fair value of derivative liabilities | $38.2K |
| Prepaid expenses and other receivable | $431.2K |
| Accounts payable - related party | $550.3K |
| Other payables and accrued liabilities | $36.7K |
| Accrued liability - related party | $9.6M |
| Franchise tax payable | -$4.1K |
| Income tax payables | -$50 |
| Net cash used in operating activities | -$1.8M |
| Payments of transactions cost | -$117.5K |
| Proceeds from issuance of common stock for PIPE investment | $2.4M |
| Purchase of treasury stock | -$29.5K |
| Net cash provided by (used in) financing activities | $2.3M |
| Net Change in Cash | $467.4K |
| Cash paid for income tax | $913 |
| Recognition of derivative liabilities upon closing of the PIPE investment | $318.3K |
No quarter-by-quarter statement was filed.
Leadership
Who has led Estrella Immunopharma, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
Board members and other officers (4)
- Board memberDengyao Jia Oct 1, 2025 to now10
- Board memberXuejun Janelle Wu Oct 10, 2023 to Oct 10, 202311
- Board memberWeston Twigg Jul 22, 2021 to Jul 22, 202112
- Board memberTao Jiang Jul 26, 2021 to Jul 26, 202113
Former names
- TradeUP Acquisition Corp.Feb 19, 2021 to Sep 20, 20232
Filings
209 filings to the SEC since October 2021: 7 annual reports, 15 quarterly reports, 60 major events, 24 insider forms, 14 large holders, 89 other. The latest 20:
- Sep 8, 20268-K CURRENT REPORT EDGAR
- Aug 26, 20264 PRIMARY DOCUMENT EDGAR
- Aug 25, 20264 EDGAR
- Aug 21, 20268-K CURRENT REPORT EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 202610-Q QUARTERLY REPORT EDGAR
- Jun 30, 20268-K CURRENT REPORT EDGAR
- May 27, 2026DEF 14A EDGAR
- May 18, 202610-Q QUARTERLY REPORT EDGAR
- May 18, 2026NT 10-Q NOTIFICATION OF LATE FILING EDGAR
- May 15, 2026SCHEDULE 13G EDGAR
- Apr 30, 202610-K/A AMENDMENT NO. 1 TO FORM 10-K EDGAR
- Apr 29, 20264 EDGAR
- Mar 18, 202610-K ANNUAL REPORT EDGAR
- Feb 13, 2026424B3 PROSPECTUS EDGAR
- Jan 23, 2026EFFECT EDGAR
- Jan 22, 2026CORRESP EDGAR
- Jan 22, 2026S-1/A REGISTRATION STATEMENT EDGAR
- Jan 16, 2026S-1/A REGISTRATION STATEMENT EDGAR
- Jan 13, 20268-K CURREN REPORT EDGAR
The 209 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
4 open-market trades by officers, directors and large owners since October 2021: 4 buys and 0 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Oct 7, 2025 | Xu JiandongChief Financial Officer | Buy | 1,000 | $1.33 | $1.3K | Form 4 |
| Sep 22, 2025 | Xu JiandongChief Financial Officer | Buy | 1,000 | $1.16 | $1.2K | Form 4 |
| Sep 11, 2025 | Xu JiandongChief Financial Officer | Buy | 100 | $1.04 | $104 | Form 4 |
| Mar 4, 2022 | Li Jianwei | Buy | 141,970 | $314,700.00 | $44.7B | Form 4 |
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 2 filings May 15, 2026 to Aug 14, 202614
- Eureka Therapeutics, Inc.SC 13D, 1 filing Oct 30, 202315
- Karpus Management, Inc.SC 13G/A, 4 filings Oct 8, 2021 to Mar 10, 202316
- ATW SPAC MANAGEMENT LLCSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202317
- BOOTHBAY FUND MANAGEMENT, LLCSC 13G/A, 2 filings Feb 4, 2022 to Jan 31, 202318
- Jianwei LiSC 13G/A, 1 filing Mar 17, 202219
- Space Summit Capital LLCSC 13G/A, 1 filing Feb 2, 202220
- K2 PRINCIPAL FUND, L.P.SC 13G/A, 1 filing Oct 8, 202121
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Armistice Capital, LLC | 3,975,220 | $4.1M | 0.1% | −123,780 |
| Vanguard Capital Management LLC | 416,852 | $433.5K | 0.0% | +34,383 |
| Geode Capital Management, LLC | 141,321 | $147.0K | 0.0% | −16,164 |
| Vanguard Fiduciary Trust Co | 64,921 | $67.5K | 0.0% | No change |
| BlackRock, Inc. | 52,033 | $54.1K | 0.0% | +12,143 |
| State Street Corp | 43,252 | $45.0K | 0.0% | No change |
| Renaissance Technologies LLC | 39,100 | $40.7K | 0.0% | −23,695 |
| Northern Trust Corp | 34,861 | $36.3K | 0.0% | +15,237 |
| Us Bancorp \de\ | 20,000 | $20.8K | 0.0% | +3,096 |
| Tower Research Capital LLC (TRC) | 3,308 | $3.4K | 0.0% | −1,551 |
| UBS Group AG | 1,721 | $1.8K | 0.0% | −13,358 |
| Toronto Dominion Bank | 1,089 | $1.1K | 0.0% | No change |
| Wolverine Asset Management LLC | 468 | $487 | 0.0% | No change |
| Barclays PLC | 126 | $131 | 0.0% | New |
| Caitong International Asset Management Co., Ltd | 2 | $2 | 0.0% | New |
13F reports cover disclosed long positions in U.S. stocks only.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9SEC EDGARLuqi Wen, Chief financial officer
- 10SEC EDGARDengyao Jia, Board member
- 11SEC EDGARXuejun Janelle Wu, Board member
- 12SEC EDGARWeston Twigg, Board member
- 13SEC EDGARTao Jiang, Board member
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21